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Abstract
 
A number of transcription factors that act as molecular switches for hematopoietic lineage decisions
have been identified. We recently described the ETS transcription factor Spi-B to be exclu-
sively expressed in plasmacytoid dendritic cells (pDCs), but not in myeloid DCs. To assess
whether Spi-B is required for pDC development we used an RNA interference knock down
approach to specifically silence Spi-B protein synthesis in CD34
 
  
 
precursor cells. We observed
that a knock down of Spi-B mRNA strongly inhibited the ability of CD34
 
  
 
precursor cells to
develop into pDCs in both in vitro assays as well as in vivo upon injection into recombination
activating gene 2
 
 
 
/
 
  
 
  
 
common
 
 
 
/
 
  
 
mice. The observed effects were restricted to the pDC lineage
as the differentiation of pro–B cells and CD14
 
  
 
myeloid cells was not inhibited but slightly ele-
vated by Spi-B knock down. Knock down of the related ETS factor PU.1 also inhibited in
vitro development of CD34
 
  
 
cells into pDCs. However, in contrast to Spi-B, PU.1 knock
down inhibited B cell and myeloid cell development as well. These results identify Spi-B as a
key regulator of human pDC development.
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Introduction
 
DCs are very efficient in inducing adaptive immune responses,
but these cells can also be involved in tolerance induction
and the regulation of innate immunity. There are different
subsets of DCs with distinct cell surface phenotypes, func-
tions, and anatomical localization (1). One member of the
DC lineage is the plasmacytoid DC (pDC) precursor (2),
also referred to as natural interferon-producing cells (3).
pDCs express Toll-like receptors 7 and 9 and have the ca-
pacity to produce high levels of type I interferons that
block viral replication, indicating that these cells play an
important role in innate immunity (4).
The developmental relationship of pDCs with other DC
types is unclear. It has been proposed that pDCs originate
from lymphoid precursors (5, 6). However, recent findings
indicate that pDCs cannot be simply connected to either
lymphoid or myeloid lineages (7, 8). Previously we have
shown that Flt3L can drive development of human pDCs
and myeloid precursors from CD34
 
  
 
CD45RA
 
  
 
precursor
cells in vitro (9). More recently it has been found in mouse
models that the DC precursor activity, including that of
pDCs and myeloid DCs, is contained within Flt3
 
  
 
lym-
phoid as well as myeloid precursors (7, 8), indicating that a
DC developmental program can be induced in both lym-
phoid and myeloid precursors.
A detailed study of the transcriptional programs that
drive DC development may contribute to an understanding
of the developmental hierarchy of various DC populations.
Various transcription factors have been described to control
development of pDCs and other DC populations. Tran-
scription factors that have been implicated are Rel-B (10),
PU.1 (11), STAT3 (12), and interferon consensus sequence
binding protein (ICSBP)/interferon regulatory factor (IRF)-8
(13). IRF-8 is the only factor identified so far that appears
to selectively control pDC development, as mice deficient
for this factor lack pDCs but have normal numbers of
CD11b
 
  
 
DCs (13). Recently we have found the ETS fam-
ily member Spi-B in a genetic search aimed to identify
genes specifically expressed in pDCs, but not in CD14
 
 
 
monocytes and monocyte-derived DCs (14). Spi-B is
closely related to PU.1, sharing 67% DNA and 43% over-
all amino acid sequence identity, but these factors differ in
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tissue expression profile and function. Spi-B is expressed in
pDCs, CD34
 
  
 
precursor cells (14), and in mature B cells,
but in contrast to PU.1, not in myeloid cells as monocytes
and neutrophils (15). The two ETS factors are also func-
tionally different because in contrast to Spi-B (16), PU.1 is
required for development of myeloid cells and B cells (17,
18). We documented that ectopic expression of human Spi-B
in CD34
 
  
 
progenitor cells moderately stimulated devel-
opment of pDCs in vitro while inhibiting development of
T, B, and NK cells (14), strongly suggesting a role of Spi-B
in pDC differentiation. However, because the effects of
Spi-B inactivation on human pDC development were not
analyzed and no information is available about the status of
pDCs in Spi-B–deficient mice, the question whether Spi-B
is required for pDC development remained unresolved.
In this paper we have applied RNA interference to sta-
bly down-regulate Spi-B in CD34
 
  
 
progenitor cells. Over-
expression of short interfering RNA (siRNA) was achieved
by retrovirus-mediated transduction using a vector based
on the RETROSUPER vector, which was described by
Brummelkamp et al. (19). Expression of Spi-B siRNA in
CD34
 
  
 
progenitors resulted in a strong inhibition of pDC
development. In contrast, development of B cells and CD14
 
 
 
myeloid cells was stimulated by Spi-B siRNA.
 
Materials and Methods
 
Reagents and Monoclonal Antibodies.
 
Monoclonal antibodies to
CD10, CD11c, CD14, CD19, and CD123 conjugated to PE,
PerCP, PeCy7, APC, or APCCy7 were purchased from Becton
Dickinson. Anti–BDCA2-PE was obtained from Miltenyi Biotec
and anti–NGFR-PE was obtained from Chromaprobe. The cy-
tokines IL-7, stem cell factor, and trombopoeitin were obtained
from R&D Systems. Flt3L was provided by G. Wagemaker (Er-
asmus University, Rotterdam, Netherlands). HeLa and Phoenix
cells were cultured in Iscove’s medium (GIBCO BRL) with 8%
FCS. OP9 cells were provided by T. Nakano (Osaka University,
Osaka, Japan) and maintained in MEM
 
  
 
(GIBCO BRL) with
20% FCS (20).
 
Constructs and Retroviral Production.
 
The retroviral construct,
LZRS IRES GFP, used to overexpress Spi-B and PU.1 was de-
scribed previously (14). For knock down experiments, the
pSUPER construct described previously by Brummelkamp et al.
(19) was adapted. To allow for identification of transduced cells by
flow cytometry, a GFP-expressing cassette was added such that
the pol3 promoter for transcription of the RNAi probe and the
pgk promoter driving GFP expression were positioned in oppo-
site directions. The RNAi sequences specifically targeting either
the Spi-B (5
 
 
 
-GATCGCTGTGTGTCTGTAA) or PU.1 (5
 
 
 
-
GTCCGTATGTAAATCAGAT) mRNA were designed using
Ambion’s siRNA Target Finder (http://www.ambion.com). Se-
quences were inserted into the BglII–HindIII sites of pSUPER
GFP. The pol3 RNAi sequence pgk GFP cassette was then sub-
cloned into a self-inactivating derivative of the LZRS retroviral
construct (21). The SIN vector was chosen to prevent promoter
interference by retroviral promoters in the LTR. For in vitro
studies, an RNAi construct targeting the sea pansy (
 
Renilla renifor-
mis
 
) luciferase sequence was used as a control (22). For in vivo
experiments, control LZRS IRES with a downstream signaling-
incompetent mutant of the nerve growth factor receptor (
 
 
 
NGFR)
and Spi-B RNAi/GFP-transduced progenitor cells were coin-
jected in SCID RAG-2
 
 
 
/
 
  
 
 
 
c
 
 
 
/
 
  
 
mice. Using these constructs,
GALV-pseudotyped retroviruses were produced using the Phoe-
nix packaging cell line.
 
RT-PCR.
 
To establish degradation of mRNA by the Spi-B
and PU.1 RNAi constructs, an RT-PCR was performed on
transfected HeLa cells. 1 
 
 
 
g of the LZRS Spi-B or PU.1 con-
structs was cotransfected with 10 
 
 
 
g of either the pSIN SUPER
Spi-Bi, PU.1i, or Renilla-i knock down constructs described
above. 5 d after transfection, RT-PCR was performed on total
cDNA. The PCR primers were as follows: Spi-B: 5
 
 
 
-GGAGT-
GCTGCCCTGCCATAA and 3
 
 
 
-CCCCCACCCCAGATGAG-
ATT; PU.1: 5
 
 
 
-TGG AAG GGT TTC CCC TCG TC and 3
 
 
 
-
TGC TGT CCT TCA TGT CGC CG; and HPRT: 5
 
 
 
-TATG-
GACAGGACTGAACGTCTTGC and 3
 
 
 
-GACACAAACAT-
GATTCAAATCCCTGA.
 
Isolation of CD34
 
  
 
Cells from Fetal Liver.
 
Human fetal tissues
were obtained from elective abortions. The use of fetal tissue was
approved by the Medical Ethical Committee of the Academic
Medical Center and was contingent on informed consent. Gesta-
tional age was determined by ultrasonic measurement of the di-
ameter of the skull and ranged from 14 to 20 wk. Fetal liver
CD34
 
  
 
cells were isolated as described previously (5).
 
Retroviral Transduction and Differentiation Assays.
 
Retroviral
transductions of CD34
 
  
 
fetal liver cells were performed as de-
scribed previously (5). The development of pDCs, pro–B cells,
and CD14
 
  
 
myeloid cells was assessed by coculturing 50,000
CD34
 
  
 
progenitor cells with 30,000 OP9 cells. Cultures were
performed in Yssels medium (23) with 8% FCS supplemented
with 5 ng/ml IL-7 and 5 ng/ml Flt3L. Stromal cells and cyto-
kines were refreshed at 7 d of culture.
To study lymphoid development in vivo, sublethally irradiated
(350 cGy) neonatal (
 
 
 
1 wk old) RAG-2
 
 
 
/
 
  
 
 
 
c
 
 
 
/
 
  
 
mice (24) that
completely lack T, B, and NK lymphocytes were injected intra-
hepatically with 10
 
6 
 
cells containing a 3:2 mixture of Spi-Bi/GFP
and control 
 
 
 
NGFR-transduced CD34
 
  
 
CD38
 
  
 
progenitor cells
(the transduction efficiencies for both constructs were 15–25%).
Humanized RAG-2
 
 
 
/
 
  
 
 
 
c
 
 
 
/
 
  
 
mice were analyzed at 5–8 wk after
injection for the development of human pDCs, B cells, and my-
eloid cells. Flow cytometric analyses were performed on an
LSRII FACS analyzer (Becton Dickinson). All animal experi-
ments were approved by the Animal Experiment Review Board
of the Academic Medical Center.
 
Results and Discussion
 
Spi-B and PU.1 RNAi Reduce the Amount of Spi-B and
PU.1 mRNA, Respectively, and Impair pDC Development In
Vitro.
 
We have documented that overexpression of Spi-B
in CD34
 
  
 
precursor cells stimulates differentiation into pDCs
(14). To determine whether Spi-B is required for pDC de-
velopment we used an approach to knock down Spi-B in
CD34
 
  
 
cells. We designed a retroviral construct directing
the synthesis of siRNAs to specifically target and degrade
the Spi-B mRNA. In parallel we made an RNAi construct
for the related transcription factor PU.1. The RNAi con-
structs were tested for their ability to reduce the amounts of
Spi-B and PU.1 mRNA, respectively (Fig. 1 A). To con-
trol for introduction of siRNA-expressing constructs we
prepared an RNAi construct targeting the nonexpressed
Renilla luciferase RNA (22). HeLa cells transfected with 
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the Spi-B overexpression and Spi-B RNAi constructs (Fig.
1 A, lane 2) showed decreased levels of Spi-B mRNA as
compared with cells cotransfected with the Renilla-i (Fig. 1
A, lane 1) or PU.1i (Fig. 1 A, lane 3) vectors. This clearly
indicates that the Spi-Bi construct is capable of blocking
Spi-B protein synthesis. A similar reduction of PU.1 mRNA
was observed for cells containing both the PU.1 and PU.1i
constructs (Fig. 1 A, lane 5), showing that both constructs
are functional.
Having determined the specific down-regulation of Spi-B
and PU.1 mRNAs by the RNAi constructs, we tested
the effects of Spi-B and PU.1 siRNA on pDC develop-
ment using an assay described previously (5, 14). CD34
 
 
 
CD38
 
  
 
human hematopoietic progenitor cells isolated
from fetal liver were transduced with the Renilla, PU.1, or
Spi-B siRNA expression constructs. To allow differentia-
tion into pDCs, the mixture of transduced and nontrans-
duced progenitor cells was cocultured with the murine
bone marrow stromal cell line OP9 in the presence of IL-7
and Flt3L for 7 d. Within this time frame the cell numbers
in these cultures remained the same and thus relative per-
centages can be considered representative for absolute cell
numbers. Fig. 1 B and Table I clearly show that both the
PU.1i/GFP
 
  
 
and Spi-Bi/GFP
 
  
 
progenitor cells are severely
impaired in their differentiation toward CD123
 
hi 
 
BDCA2
 
 
 
pDCs as compared with nontransduced cells or cells trans-
duced with the Renilla-i/GFP control construct.
These experiments show that introduction of RNAi-
inducing DNA fragments in CD34
 
  
 
cells using a retroviral
vector with the GFP marker allows for expression of
siRNAs, which efficiently knock down the genes of inter-
est. We demonstrate that the expression of Spi-B siRNA or
Figure 1. Knock down of Spi-B and PU.1 impair
pDC development in vitro. (A) RNA degradation by
Spi-B and PU.1 RNAi constructs in transfected
HeLa cells. RT-PCR on Spi-B: lane 1, Spi-B plus
Renilla-i; lane 2, Spi-B plus Spi-Bi; lane 3, Spi-B
plus PU.1i. RT-PCR on PU.1: lane 4, PU.1 plus
Renilla-i; lane 5, PU.1 plus PU.1i; lane 6, PU.1
plus Spi-Bi. RT-PCR on the house keeping en-
zyme HPRT was performed as a loading control.
(B) CD34  CD38  human fetal liver cells were ret-
rovirally transduced with PU.1i/GFP, Spi-Bi/GFP,
or Renilla-i/GFP control virus. Transduced and
nontransduced cells were cultured on OP9 cells with
IL-7 and Flt3L and analyzed for the development of
pDCs by flow cytometry at 7 d of culture. Dot
plots represent the transduced (GFP ) and non-
transduced (GFP ) hematopoietic cell (CD45 )
populations. Numbers represent percentages of
pDCs as CD123hi BDCA2  gated events.
 
Table I.
 
Spi-B RNAi Specifically Impairs pDCs and Stimulates Myeloid and B Cell Differentiation In Vitro
 
% BDCA2
 
  
 
CD123
 
hi
 
% CD14
 
  
 
CD11c
 
  
 
% CD10
 
  
 
CD19
 
 
 
Experiment no. Renilla-i PU.1i Spi-Bi Renilla-i PU.1i Spi-Bi Renilla-i PU.1i Spi-Bi
1 6.3 1.5 0.9 13.5 4.6 22.5 2.0 0.1 10.1
2 12.7 1.7 7.1 29.9 22.3 41.5 1.2 0.4 7.5
3 19.1 4.7 1.8 35.1 ND 44.0 18.8 16.3 28.1
4 10.4 5.9 2.9 18.5 ND 23.4 1.1 0.6 13.1
5 10.0 ND 1.7 19.0 ND 31.4
6 3.8 ND 0.8 1.8 ND 3.1
Sample vs. Renilla-i
 
  
 
p-value 0.04 0.01 0.05 0.01 0.05 0.00
Statistical analysis on the percentages of pDCs, B cells, and myeloid cells differentiated from CD34
 
  
 
CD38
 
  
 
progenitors in the OP9 assay was
performed using a paired two-tailed Student’s 
 
t
 
 test. 
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PU.1 siRNA in CD34
 
  
 
cells severely compromised their
development into pDCs in vitro. These effects were spe-
cific and not due to possible induction of interferon re-
sponses because expression of an irrelevant siRNA (Re-
nilla) did not affect pDC development.
 
Reduced Spi-B Levels Stimulate Myeloid and B Cell Differen-
tiation In Vitro.
 
In addition to a stimulating effect on pDC
development, forced expression of Spi-B in human he-
matopoietic progenitor cells has a strong inhibitory effect
on their development into B cells (14). Therefore, we ex-
pected that knocking down Spi-B would either not affect
or stimulate B cell development. Furthermore, PU.1 is ab-
solutely required for development of murine B cells and
also of myeloid cells (18). Therefore, it was of interest to
compare the effects of PU.1 and Spi-B siRNAs on devel-
opment of human B and myeloid cells. In the coculture as-
say used for pDC development, CD34
 
  
 
CD38
 
  
 
fetal liver
precursor cells also develop into myeloid and pro–B cells.
After 11 d, the coculture assay was analyzed for the pres-
ence of myeloid (CD14 and CD11c) or pro–B (CD19 and
CD10) cells. Consistent with a developmental block by
overexpression of Spi-B, Spi-B knock down led to in-
creased percentages of myeloid and pro–B cells as com-
pared with the nontransduced or Renilla-i/GFP control
cultures (Fig. 2 and Table I). The stimulation of myeloid
and pro–B cell development was observed only after re-
duction of Spi-B protein. Reduced levels of PU.1 not only
blocked pDCs, but also inhibited myeloid and B cell devel-
opment, consistent with findings in mouse models that he-
matopoietic progenitors of PU.1
 
 
 
/
 
  
 
fetal liver cells failed to
generate B or myeloid cells (18). Our findings indicate that
both Spi-B and PU.1 play a role in human pDC develop-
ment. Because PU.1 also inhibited development of B cells
and myeloid cells, it is likely that the PU.1 knock down in-
hibits pDC development before the split of B cells, myeloid
cells, and pDCs.
 
Reduced Spi-B Levels Block pDCs, but Stimulate Myeloid
and B Cell Differentiation In Vivo.
 
To confirm the in vitro
observations in an in vivo setting, we made use of a human-
ized SCID mouse model (24). We modified this model in
that we injected irradiated newborn RAG-2
 
 
 
/
 
  
 
 
 
c
 
 
 
/
 
  
 
mice
directly in the liver with CD34
 
  
 
CD38
 
  
 
progenitor cells (25,
26). In this model development of pDCs, B cells and my-
eloid cells are already observed within 5 wk after injection.
To compensate for the experimental variations between in-
dividual mice and to take into account differences in engraft-
Figure 2. Knock down of Spi-B, but not
PU.1, stimulates development of myeloid cells
and pro–B cells in vitro. CD34  CD38  human
fetal liver cells were retrovirally transduced with
PU.1i/GFP, Spi-Bi/GFP, or Renilla-i/GFP
control virus. Transduced and nontransduced
cells were cultured on OP9 cells with IL-7 and
Flt3L and analyzed for the presence of myeloid
cells and pro–B cells by flow cytometry at 11 d
of culture. Dot plots represent the transduced
(GFP ) hematopoietic cell (CD45 ) popula-
tions. Numbers represent percentages of B cells
(CD10  CD19 ) and myeloid cells (CD11c 
CD14 ).
 
Table II.
 
Spi-B RNAi Impairs pDCs and Stimulates Myeloid and B Cell Differentiation In Vivo
 
Bone marrow
BDCA2
 
 
 
Bone marrow
CD14
 
 
 
Bone marrow
CD19
 
 
 
Spleen
BDCA2
 
 
 
Liver
BDCA2
 
 
 
Experiment no.
 
 
 
NGFR Spi-Bi Ratio
 
a
 
 
 
NGFR Spi-Bi Ratio
 
a
 
 
 
NGFR Spi-Bi Ratioa  NGFR Spi-Bi Ratioa  NGFR Spi-Bi Ratioa
1 852 45 5 406 1,270 313 1,461 1,769 121 83 8 10 3,445 0 0
2 4,476 241 5 3,545 3,744 106 496 1,160 234 307 11 3 43 0 0
3 1,750 835 48 770 1,582 206 16 2,054 12,783 309 29 9 97 23 24
a 100%.
The numbers represent absolute numbers of output cells of each subpopulation derived from 1,000 transduced input progenitor cells. The ratios
( 100%) are representative for the relative increase or decrease of the Spi-Bi/GFP  cells compared to the control  NGFR  cells.Schotte et al. Brief Definitive Report 1507
ment of retrovirally transduced (cycling) cells versus non-
transduced (mostly resting) CD34  CD38  cells, Spi-Bi/
GFP-transduced cells were coinjected with CD34  CD38 
cells transduced with a control construct expressing a signal-
ing-incompetent mutant of the NGFR. At 5 wk after injec-
tion of both Spi-Bi/GFP and control  NGFR-transduced
and nontransduced cells, we analyzed bone marrow, liver,
spleen, thymus, and peripheral blood for the presence of hu-
man pDCs, B cells, and myeloid cells. Fig. 3 and Table II
clearly show a strong reduction in the percentages and abso-
lute cell numbers of BDCA2  pDCs in the Spi-Bi/GFP 
population as compared with the control  NGFR  cells in
the bone marrow, spleen, and liver. Importantly, in the bone
marrow we observed a higher percentage and absolute cell
number of myeloid cells (CD14 ) and B cells (CD19 ) in
the Spi-Bi/GFP  as compared with the control  NGFR 
population, indicating that development of CD14   and
CD19  cells is stimulated by knocking down Spi-B.
Our findings clearly indicate that Spi-B is specifically re-
quired for development of human pDCs. These data add to
observations that mice deficient for ICSBP/IRF-8 lack
pDCs and CD8   DCs (13). Thus, both the ETS factor
Spi-B and the IRF factor ICSBP/IRF-8 appear to be es-
sential for pDC development. Interestingly, the ETS and
IRF factors can cooperatively assemble on composite ETS-
IRF DNA (EICE) elements, which were initially discov-
ered in the immunoglobulin light chain enhancers but have
later been found in promoters and enhancers of B lym-
phoid and myeloid genes (27). Similar to PU.1 and IRF-4,
Spi-B and ICSBP/IRF-8 assemble in an ETS–IRF ternary
complex of which the crystal structure was resolved re-
cently (27). Given that both ICSBP/IRF-8 and Spi-B are
required for pDC development, the structural data of
Escalante et al. (27) make it very likely that Spi-B and
ICSBP/IRF-8 cooperate in controlling pDC development.
Recent data have made clear that pDCs can develop
both from Flt3  lymphoid as well as myeloid precursors (7,
8) and not solely from lymphoid precursors as we hypothe-
sized earlier (5). More recently, Shigematsu et al. (28) re-
ported that pDCs developing from myeloid precursors are
phenotypically and functionally similar to those developing
from lymphoid precursors. Interestingly, pDCs express
pT  and have IgH D-J rearrangements regardless of their
developmental origin. Importantly, both pDC develop-
mental pathways result in expression of Spi-B (28). These
findings strongly suggest that the pDC program can be in-
duced by the interaction of Spi-B and ICSBP/IRF-8 in
both lymphoid and myeloid precursor cells. It will be of in-
terest to elucidate the mechanisms of induction and opera-
tion of this program.
Id proteins have also been implicated in the control of
pDC development. We have demonstrated that overex-
pression of Id2 and Id3 strongly inhibit development of
pDCs (5). Overexpression of DNA encoding the bHLH
factors HEB and E2A into CD34  CD38  cells stimulated
pDC development in a way comparable to Spi-B (unpub-
lished data), which may suggest that these factors play a role
in pDC development. The involvement of bHLH factors
and Spi-B in pDC development raises the question whether
these factors are collaborating in development of pDCs.
This is possible, however, in contrast to Spi-B knock
down, the forced expression of Id2 and Id3 strongly inhib-
its B cell development (29), which implies that either an-
other yet to be identified bHLH factor cooperates with
Spi-B in controlling pDC development or Spi-B collabo-
rates with factors such as HEB, E12, and E47 in a cell con-
text–dependent way.
The finding that Spi-B is specifically involved in devel-
opment of pDCs suggests that it is a master gene for this
cell type. This idea is supported by our previous findings
that overexpression of Spi-B inhibits development of T
cells, B cells, and NK cells (14), indicating that like with
other master genes, expression of Spi-B in CD34  precur-
sor cells is incompatible with alternative cell fates. Consis-
tent with this notion, down-regulation of Spi-B stimulates
development of “alternative” cell lineages such as B cells
Figure 3. Spi-B knock down hampers pDCs, but not B and myeloid,
development in vivo. 5–7-d-old irradiated neonatal RAG-2 /   c
 / 
knockout mice were reconstituted with a mixture of Spi-Bi/GFP-trans-
duced, control  NGFR–transduced, and nontransduced CD34  CD38 
progenitor cells. Pictures show the transduced Spi-Bi/GFP  and control
 NGFR  human (CD45 ) cell populations present in the bone marrow,
spleen, and liver 5 wk after injection: pDC (BDCA2 ), B cells (CD19 )
and myeloid cells (CD14 ). The data shown represents one of three ex-
periments with comparable results.Spi-B RNAi Inhibits Human pDC Development 1508
and CD11c  CD14  myeloid cells. Based on the observa-
tion that overexpression of Spi-B impairs T cell develop-
ment in vitro, it was expected that lowered levels of Spi-B
would also stimulate T cell development. However, after
injection of the mixture of Spi-Bi/GFP-transduced and
control   NGFR–transduced CD34  progenitor cells in
RAG-2 /   c
 /  mice, we observed high levels of control
 NGFR  cells, but not Spi-Bi/GFP  cells, in the thymus
(not depicted), suggesting that Spi-B is either required for
population of the thymus by precursor cells or Spi-B plays
a crucial role in the early stages of development of T cells
in the thymus. Experiments to investigate the effects of
down-regulation of Spi-B on T cell development in vitro
and in vivo are currently being performed in our lab.
This paper demonstrates the power of the RNAi ap-
proach for the study of human hematopoietic develop-
ment. We have also demonstrated that the combination of
this approach with the human SCID mouse model pro-
vides unique tools to unravel the roles of transcription fac-
tors and other gene products in human hematopoietic de-
velopment in an in vivo setting.
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